EW

EW

USD

Edwards Lifesciences Corporation Common Stock

$84.150+1.100 (1.325%)

实时价格

Healthcare
医疗设备
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$83.050

最高价

$84.830

最低价

$82.890

成交量

2.64M

公司基本面

市值

49.4B

所属行业

医疗设备

国家/地区

United States

交易统计

平均成交量

4.58M

交易所

NYQ

货币

USD

52周价格范围

最低价 $64.89当前价 $84.150最高价 $87.09

相关新闻

Analyst Upgrades

Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $90

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences with a Hold and raises the price target from $87 to $90.

查看更多
Truist Securities Maintains Hold on Edwards Lifesciences, Raises Price Target to $90
Analyst Upgrades

Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $99

Barclays analyst Matt Miksic maintains Edwards Lifesciences with a Overweight and raises the price target from $95 to $99.

查看更多
Barclays Maintains Overweight on Edwards Lifesciences, Raises Price Target to $99
Analyst Upgrades

Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $96

Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences with a Buy and raises the price target from $95 to $96.

查看更多
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $96
Analyst Upgrades

JP Morgan Maintains Neutral on Edwards Lifesciences, Raises Price Target to $90

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences with a Neutral and raises the price target from $85 to $90.

查看更多
JP Morgan Maintains Neutral on Edwards Lifesciences, Raises Price Target to $90
Analyst Upgrades

Goldman Sachs Maintains Buy on Edwards Lifesciences, Raises Price Target to $104

Goldman Sachs analyst David Roman maintains Edwards Lifesciences with a Buy and raises the price target from $94 to $104.

查看更多
Goldman Sachs Maintains Buy on Edwards Lifesciences, Raises Price Target to $104
Analyst Upgrades

Piper Sandler Reiterates Overweight on Edwards Lifesciences, Raises Price Target to $95

Piper Sandler analyst Adam Maeder reiterates Edwards Lifesciences with a Overweight and raises the price target from $90 to $95.

Analyst Upgrades

RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $95

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences with a Outperform and raises the price target from $89 to $95.